Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002798 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
A Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 1
- Study location
NCT00002798: Completed Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes, sponsored by National Cancer Institute (NCI).
NCT00002798 is a Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 880 participants, above the 77-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (1043% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002798, a Phase 3 study of Chronic Myelomonocytic Leukemia and de Novo Myelodysplastic Syndromes, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
Conditions Studied
Interventions
- DRUG fludarabine phosphate
- PROCEDURE allogeneic bone marrow transplantation
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
- DRUG therapeutic hydrocortisone
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 1996-08 |
| Phase | Phase 3 |
What the finished NCT00002798 record still lists
NCT00002798 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 77-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (1043% higher).
The record links to 10 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT00002798 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00002798 about?
NCT00002798 is a clinical study titled "Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome". Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividin...
What is the current status of trial NCT00002798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 1996-08.
What conditions does trial NCT00002798 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Childhood Myelodysplastic Syndromes, Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a).
What interventions are being tested in trial NCT00002798?
The interventions under investigation include: fludarabine phosphate (DRUG), allogeneic bone marrow transplantation (PROCEDURE), asparaginase (DRUG), daunorubicin hydrochloride (DRUG), therapeutic hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT00002798?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002798 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002798's enrollment target sits among peer trials
880 1st of 73 higher than 73 of 73 other Chronic Myelomonocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myelomonocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
COMPLETED · Phase 3
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia